Is Halozyme Therapeutics, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Halozyme Therapeutics, Inc. moved from expensive to fair. The company appears fairly valued based on its current metrics. The P/E ratio stands at 14, the EV to EBITDA ratio is 10.96, and the PEG ratio is notably low at 0.22, indicating strong growth potential relative to its price.
In comparison to its peers, Halozyme's P/E ratio is lower than Illumina, Inc. at 19.09 and BioMarin Pharmaceutical, Inc. at 15.17, suggesting it is competitively priced within the industry. The company's strong ROE of 100.64% and ROCE of 48.11% further support its valuation. Over the past year, Halozyme has returned 28.21%, outperforming the S&P 500's return of 14.08%, reinforcing its position as a solid investment.